Focus: Trans-Pacific Partnership and global health concerns

24 July 2015
tppbig

Doctors without Borders/Médecins Sans Frontières (MSF) on Friday called for the removal of access to medicines provisions in the Trans-Pacific Partnership (TPP) trade deal, saying if not checked it could lock out a major chunk of the global population from receiving affordable medicines.

The TPP is a free-trade agreement (FTA), an agreement targeted at establishing a new Pacific trade zone and removing barriers with a view to promote international trade. The TPP is currently being negotiated by 12  countries from Australia to the USA. These nations include both developed as well as emerging economies, and account for about 40% of global gross domestic product. The meet in Maui starting next week is expected to seal the agreement.

The aim of the TPP is to strengthen trade associations by way of addressing issues like government procurement, intellectual property protection as well as the conduct of state-­owned enterprises.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical